Boston based Alexion Pharmaceuticals Inc. shares shed 0.93% to $184.54 Tuesday. This proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.20% to 4,343.54 and Dow Jones Industrial Average DJIA falling 0.60% to 34,577.37.
Alexion Pharmaceuticals Inc. closed $1.98 short of its 52-week high ($186.52), which the company achieved on July 2nd. The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Gilead Sciences Inc. GILD fell 1.28% to $68.41, Vertex Pharmaceuticals Inc. VRTX fell 0.24% to $200.05, and Regeneron Pharmaceuticals Inc. REGN fell 0.24% to $582.25.
The megadeal, announced in December, would allow the Anglo-Swedish group to boost its growing presence in immunology and rare diseases.The deal will see Alexion shareholders paid US$175 for each share, made up of US$60 in cash and 2.1243 American depositary shares (ADSs), which each represent one-half of one ordinary AstraZeneca share.